CoChat

Noise‐induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon

Open access
Stone, Barbara M., Turner, Claire, Mills, Sue L., Paty, Isabelle, Patat, Alain, Darwish, Mona, Danjou, Philippe · 2002 · British Journal of Clinical Pharmacology
Cited by 34

The DOI matches its Crossref record.

Abstract

Aims The primary objective of the study was to assess the residual effects of zaleplon in the morning, 4 h after a middle‐of‐the‐night administration. The secondary objective was to investigate the effectiveness of zaleplon in promoting sleep in healthy volunteers with noise‐induced sleep maintenance insomnia. Methods Thirteen healthy male and female volunteers (aged 20–30 years) with normal hearing, who were sensitive to the sleep‐disrupting effects of noise, participated in a double‐blind, placebo‐ and active‐drug controlled, four‐period cross‐over study. The subjects were permitted to sleep for 5 h (22.45–03.45 h) in a quiet environment before they were awoken. At 04.00 h they ingested 10 mg zaleplon, 20 mg zaleplon, 7.5 mg zopiclone (active control), or placebo before a second period of sleep (04.00–08.00 h), during which they were exposed to an 80 dB(A) 1 kHz pure tone pulse with an inter‐tone interval of 1 s and a duration of 50 ms. The sound stimulus was stopped after 10 min of persistent sleep or after 2 h if the subject had not fallen asleep. Residual effects were assessed at 08.00 h (4 h after drug administration) using the digit symbol substitution test (DSST), choice reaction time (CRT), critical flicker fusion (CFF), and immediate and delayed free recall of a 20 word list. The data were analysed by analysis of variance. A Bonferroni adjustment was made for the three active treatments compared with placebo. Results There were no residual effects of zaleplon (10 and 20 mg) compared with placebo. Zopiclone impaired memory by delaying the free recall of words (P = 0.001) and attenuated performance on DSST (P = 0.004) and CRT (P = 0.001), compared with placebo. Zaleplon reduced the latency to persistent sleep (10 mg, P = 0.001; 20 mg, P = 0.014) and the 20 mg dose reduced stage 1 sleep (P = 0.012) compared with placebo. Zopiclone reduced stage 1 sleep (P = 0.001), increased stage 3 sleep (P = 0.0001) and increased total sleep time (P = 0.003), compared with placebo. Conclusions Zaleplon (10 mg and 20 mg), administered in the middle of the night 4 h before arising, shortens sleep onset without impairing next‐day performance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.-5251.2001.01520.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 34

Metadata

Authors
Stone, B. M., Turner, C., Mills, S. L., Paty, I., Patat, A., Darwish, M., & Danjou, P.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2002-01-18
Volume
53
Issue
2
Pages
196-202
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1605793856
Cited by
34
References
0
FWCI
2.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Noise‐induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. https://app.cochat.ai/papers/10.1046/j.-5251.2001.01520.x
The paper
Stone, B. M., Turner, C., Mills, S. L., Paty, I., Patat, A., Darwish, M., & Danjou, P. (2002). Noise‐induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.-5251.2001.01520.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.